CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer

Annual Review of Immunology

Volumn 37, Issue , 2019, Pages 457-495

  McLane, Laura M ^a   Abdel Hakeem, Mohamed S ^a,b   Wherry, E John ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

cancer; chronic viral infections; immunotherapy; inhibitory receptors; PD 1; T cell exhaustion

Indexed keywords

ANTIGEN; CD28 ANTIGEN; CYTOKINE; PROGRAMMED DEATH 1 RECEPTOR; T BOX TRANSCRIPTION FACTOR; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR EOMES; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR T BET; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

CD8+ T LYMPHOCYTE; CELL FUNCTION; CHRONIC DISEASE; EFFECTOR CELL; EPIGENETICS; GENE LOCUS; GENETIC TRANSCRIPTION; HOMEOSTASIS; HUMAN; IMMUNOREGULATION; IMMUNOTHERAPY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; MALIGNANT NEOPLASM; METABOLIC REGULATION; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; STABLE EXPRESSION; T CELL EXHAUSTION; TRANSCRIPTION REGULATION; VIRUS INFECTION; ANIMAL; CELL AGING; CLONAL ANERGY; GENETIC EPIGENESIS; IMMUNOLOGY; METABOLISM; NEOPLASM; PHYSIOLOGY; PROCEDURES; T LYMPHOCYTE;

ANIMALS; CELLULAR SENESCENCE; CHRONIC DISEASE; CLONAL ANERGY; COSTIMULATORY AND INHIBITORY T-CELL RECEPTORS; EPIGENESIS, GENETIC; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES; VIRUS DISEASES;

EID: 85065028922     PISSN: 07320582     EISSN: 15453278     Source Type: Book Series    
DOI: 10.1146/annurev-immunol-041015-055318     Document Type: Review

References (310)

1. Sterzl J, Silverstein AM. 1967. Developmental aspects of immunity. Adv. Immunol. 6:337-459
2. Byers VS, Sercarz EE. 1968. The X-Y-Z scheme of immunocyte maturation. IV. The exhaustion of memory cells. J. Exp. Med. 127:307-25
3. Moskophidis D, Lechner F, Pircher H, Zinkernagel RM. 1993. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 362:758-61
4. Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, et al. 1998. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188:2205-13
5. Gallimore A, Glithero A, Godkin A, Tissot AC, Pluckthun A, et al. 1998. Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic Tlymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. J. Exp. Med. 187:1383-93
6. + T cells and their conversion to memory T cells. Immunol. Rev. 236:151-66
7. Wherry EJ. 2011. T cell exhaustion. Nat. Immunol. 12:492-99
8. + T cell exhaustion versus memory. Immunity 37:1130-44
9. Schietinger A, Greenberg PD. 2014. Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol. 35:51-60
10. Ahmed R, Salmi A, Butler LD, Chiller JM, Oldstone MB. 1984. Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice. Role in suppression of cytotoxic T lymphocyte response and viral persistence. J. Exp. Med. 160:521-40
11. Zinkernagel RM. 2002. Lymphocytic choriomeningitis virus and immunology. Curr. Top. Microbiol. Immunol. 263:1-5
12. Goepfert PA, Bansal A, Edwards BH, Ritter GD Jr., Tellez I, et al. 2000. A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon. J. Virol. 74:10249-55
13. + T cells in chronic human immunodeficiency virus infection. Blood 96:3094-101
14. + T cell expansions: evidence for impaired CTL effector function. Eur. J. Immunol. 31:677-86
15. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, et al. 2006. PD-1 expression on HIVspecific T cells is associated with T-cell exhaustion and disease progression. Nature 443:350-54
16. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, et al. 2000. Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med. 191:1499-512
17. + T lymphocytes after infection with hepatitis C virus. J. Virol. 75:5550-58
18. Ye B, Liu X, Li X, Kong H, Tian L, Chen Y. 2015. T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance. Cell Death Dis. 6:e1694
19. Wherry EJ, Kurachi M. 2015. Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 15:486-99
20. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. 2007. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunol. 8:239-45
21. McKinney EF, Lee JC, Jayne DR, Lyons PA, Smith KG. 2015. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature 523:612-16
22. Pauken KE, Wherry EJ. 2015. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 36:265-76
23. Zarour HM. 2016. Reversing T-cell dysfunction and exhaustion in cancer. Clin. Cancer Res. 22:1856-64
24. Mumprecht S, Schurch C, Schwaller J, Solenthaler M, Ochsenbein AF. 2009. Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood 114:1528-36
25. Schietinger A, Philip M, Krisnawan VE, Chiu EY, Delrow JJ, et al. 2016. Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis. Immunity 45:389-401
26. Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, et al. 2017. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545:60-65
27. + T cells in metastases from melanoma patients. J. Clin. Investig. 121:2350-60
28. Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, et al. 1999. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5:677-85
29. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, et al. 2009. Tumor antigenspecific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114:1537-44
30. + T cell dysfunction in melanoma patients. J. Exp. Med. 207:2175-86
31. + T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. PNAS 107:7875-80
32. + T lymphocytes in human non-small cell lung cancer. Cell Mol. Immunol. 7:389-95
33. Bengsch B, Ohtani T, Herati RS, Bovenschen N, Chang KM, Wherry EJ. 2018. Deep immune profiling by mass cytometry links human T and NK cell differentiation and cytotoxic molecule expression patterns. J. Immunol. Methods 453:3-10
34. + T-cell function in Hodgkin lymphoma patients. Blood 108:2280-89
35. Riches JC, Davies JK, McClanahan F, Fatah R, Iqbal S, et al. 2013. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood 121:1612-21
36. Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, et al. 2018. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat. Med. 24:563-71
37. Kim PS, Ahmed R. 2010. Features of responding T cells in cancer and chronic infection. Curr. Opin. Immunol. 22:223-30
38. + tumor-reactive repertoire infiltrating human tumors. J. Clin. Investig. 124:2246-59
39. Zenz T. 2013. Exhausting T cells in CLL. Blood 121:1485-86
40. + T cell expansion in melanoma patients. J. Immunol. 182:5240-49
41. + tumor-infiltrating T cells are deficient in perforin-mediated cytolytic activity due to defective microtubule-organizing center mobilization and lytic granule exocytosis. J. Immunol. 167:5042-51
42. Pauken KE, Sammons MA, Odorizzi PM, Manne S, Godec J, et al. 2016. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science 354:1160-65
43. Sen DR, Kaminski J, Barnitz RA, Kurachi M, Gerdemann U, et al. 2016. The epigenetic landscape of T cell exhaustion. Science 354:1165-69
44. Philip M, Fairchild L, Sun L, Horste EL, Camara S, et al. 2017. Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature 545:452-56
45. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, et al. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439:682-87
46. Kahan SM, Wherry EJ, Zajac AJ. 2015. T cell exhaustion during persistent viral infections. Virology 479-480:180-93
47. Iwai H, Masaoka N, Ishii T, Satoh S. 2002. A pectin glucuronyltransferase gene is essential for intercellular attachment in the plant meristem. PNAS 99:16319-24
48. Hirano F, Kaneko K, Tamura H, Dong H, Wang S, et al. 2005. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 65:1089-96
49. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. 2008. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26:677-704
50. Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, et al. 2003. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9:562-67
51. Topalian SL, Drake CG, Pardoll DM. 2012. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr. Opin. Immunol. 24:207-12
52. Iwai Y, Terawaki S, Honjo T. 2005. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int. Immunol. 17:133-44
53. Strome SE, Dong H, Tamura H, Voss SG, Flies DB, et al. 2003. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. 63:6501-5
54. + T cells. Cancer Res. 64:1140-45
55. + T cell dysfunction during chronic infection. Immunity 40:289-302
56. Moir S, Fauci AS. 2014. B-cell exhaustion in HIV infection: the role of immune activation. Curr. Opin. HIV AIDS 9:472-77
57. Bi J, Tian Z. 2017. NK cell exhaustion. Front. Immunol. 8:760
58. Catakovic K, Klieser E, Neureiter D, Geisberger R. 2017. T cell exhaustion: from pathophysiological basics to tumor immunotherapy. Cell Commun. Signal. 15:1
59. Blackburn SD, Shin H, Freeman GJ, Wherry EJ. 2008. Selective expansion of a subset of exhausted CD8 T cells by αPD-L1 blockade. PNAS 105:15016-21
60. Shin H, Blackburn SD, Blattman JN, Wherry EJ. 2007. Viral antigen and extensive division maintain virus-specific CD8 T cells during chronic infection. J. Exp. Med. 204:941-49
61. + T cells cooperate to contain chronic viral infection. Science 338:1220-25
62. + T cells that provide the proliferative burst after PD-1 therapy. Nature 537:417-21
63. Fuller MJ, Zajac AJ. 2003. Ablation of CD8 and CD4 T cell responses by high viral loads. J. Immunol. 170:477-86
64. Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R. 2003. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 77:4911-27
65. + T cell functions during chronic viral infection. PNAS 104:4565-70
66. + T cell exhaustion during chronic viral infection. Immunity 31:309-20
67. Mackerness KJ, Cox MA, Lilly LM, Weaver CT, Harrington LE, Zajac AJ. 2010. Pronounced virusdependent activation drives exhaustion but sustains IFN-gamma transcript levels. J. Immunol. 185:3643-51
68. Fuller MJ, Khanolkar A, Tebo AE, Zajac AJ. 2004. Maintenance, loss, and resurgence of T cell responses during acute, protracted, and chronic viral infections. J. Immunol. 172:4204-14
69. + T cell exhaustion during chronic viral infection. Immunity 27:670-84
70. + T cell responses during chronic infection. Nat. Immunol. 12:663-71
71. Tanchot C, Rocha B. 1997. Peripheral selection of T cell repertoires: the role of continuous thymus output. J. Exp. Med. 186:1099-106
72. Blackburn SD, Crawford A, Shin H, Polley A, Freeman GJ, Wherry EJ. 2010. Tissue-specific differences in PD-1 and PD-L1 expression during chronic viral infection: implications for CD8 T cell exhaustion. J. Virol. 84:2078-89
73. Appay V, Papagno L, Spina CA, Hansasuta P, King A, et al. 2002. Dynamics of T cell responses in HIV infection. J. Immunol. 168:3660-66
74. Jameson SC, Masopust D. 2009. Diversity in T cell memory: an embarrassment of riches. Immunity 31:859-71
75. Surh CD, Sprent J. 2008. Homeostasis of naive and memory T cells. Immunity 29:848-62
76. Lodolce JP, Boone DL, Chai S, Swain RE, Dassopoulos T, et al. 1998. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 9:669-76
77. Wherry EJ, Barber DL, Kaech SM, Blattman JN, Ahmed R. 2004. Antigen-independent memory CD8 T cells do not develop during chronic viral infection. PNAS 101:16004-9
78. Wherry EJ, Teichgraber V, Becker TC, Masopust D, Kaech SM, et al. 2003. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat. Immunol. 4:225-34
79. Radziewicz H, Ibegbu CC, Fernandez ML, Workowski KA, Obideen K, et al. 2007. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J. Virol. 81:2545-53
80. Chahroudi A, Silvestri G, Lichterfeld M. 2015.T memory stem cells and HIV: a long-term relationship. Curr. HIV/AIDS Rep. 12:33-40
81. Masopust D, Vezys V, Usherwood EJ, Cauley LS, Olson S, et al. 2004. Activated primary and memory CD8Tcells migrate to nonlymphoid tissues regardless of site of activation or tissue of origin. J. Immunol. 172:4875-82
82. Beltra JC, Bourbonnais S, Bedard N, Charpentier T, Boulange M, et al. 2016. IL2Rβ-dependent signals drive terminal exhaustion and suppress memory development during chronic viral infection. PNAS 113:E5444-53
83. Pellegrini M, Calzascia T, Elford AR, Shahinian A, Lin AE, et al. 2009. Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies. Nat. Med. 15:528-36
84. Wherry EJ, Ahmed R. 2004. Memory CD8T-cell differentiation during viral infection. J. Virol. 78:5535-45
85. Utzschneider DT, Legat A, Fuertes Marraco SA, Carrie L, Luescher I, et al. 2013. T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion. Nat. Immunol. 14:603-10
86. Kasprowicz V, Kang YH, Lucas M, Schulze zur Wiesch J, Kuntzen T, et al. 2010. Hepatitis C virus (HCV) sequence variation induces an HCV-specific T-cell phenotype analogous to spontaneous resolution. J. Virol. 84:1656-63
87. Jamieson BD, Yang OO, Hultin L, Hausner MA, Hultin P, et al. 2003. Epitope escape mutation and decay of human immunodeficiency virus type 1-specific CTL responses. J. Immunol. 171:5372-79
88. + T cells are maintained after cessation of chronic antigen stimulation. Nat. Commun. 8:15050
89. + Tcells sustain the immune response to chronic viral infections. Immunity 45:415-27
90. + T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 10:29-37
91. + T cells correlates with disease progression and defines a reversible immune dysfunction. Nat. Immunol. 8:1246-54
92. + T cell survival in HIV infection. J. Exp. Med. 203:2281-92
93. + T cells leads to reversible immune dysfunction. Nat. Med. 12:1198-202
94. + T cells is linked to antigen recognition and T cell differentiation. PLOS Pathog. 6:e1000947
95. Urbani S, Amadei B, Tola D, Massari M, Schivazappa S, et al. 2006. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J. Virol. 80:11398-403
96. + T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation. J. Hepatol. 61:1212-19
97. Velu V, Titanji K, Zhu B, Husain S, Pladevega A, et al. 2009. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 458:206-10
98. Attanasio J, Wherry EJ. 2016. Costimulatory and coinhibitory receptor pathways in infectious disease. Immunity 44:1052-68
99. MacIver NJ, Michalek RD, Rathmell JC. 2013. Metabolic regulation of T lymphocytes. Annu. Rev. Immunol. 31:259-83
100. Buck MD, O'Sullivan D, Pearce EL. 2015.T cellmetabolism drives immunity. J. Exp. Med. 212:1345-60
101. O'Sullivan D, Pearce EL. 2015. Targeting T cell metabolism for therapy. Trends Immunol. 36:71-80
102. + T cell memory development. Immunity 36:68-78
103. Patsoukis N, Brown J, Petkova V, Liu F, Li L, Boussiotis VA. 2012. Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. Sci. Signal. 5:ra46
104. Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, et al. 2005. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell. Biol. 25:9543-53
105. Patsoukis N, Bardhan K, Chatterjee P, Sari D, Liu B, et al. 2015. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat. Commun. 6:6692
106. + T cell exhaustion. Immunity 45:358-73
107. Scharping NE, Menk AV, Moreci RS, Whetstone RD, Dadey RE, et al. 2016. The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction. Immunity 45:374-88
108. + Tcells during chronic infection. Immunity 41:802-14
109. Frauwirth KA, Thompson CB. 2004. Regulation of T lymphocyte metabolism. J. Immunol. 172:4661-65
110. Hui E, Cheung J, Zhu J, Su X, Taylor MJ, et al. 2017. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science 355:1428-33
111. Kamphorst AO, Wieland A, Nasti T, Yang S, Zhang R, et al. 2017. Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science 355:1423-27
112. Schurich A, Pallett LJ, Jajbhay D, Wijngaarden J, Otano I, et al. 2016. Distinct metabolic requirements of exhausted and functional virus-specific CD8 T cells in the same host. Cell Rep. 16:1243-52
113. Pearce EL, Poffenberger MC, Chang CH, Jones RG. 2013. Fueling immunity: insights into metabolism and lymphocyte function. Science 342:1242454
114. O'Neill LA, Pearce EJ. 2016. Immunometabolism governs dendritic cell and macrophage function. J. Exp. Med. 213:15-23
115. Chang CH, Qiu J, O'Sullivan D, Buck MD, Noguchi T, et al. 2015. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162:1229-41
116. Kleffel S, Posch C, Barthel SR, Mueller H, Schlapbach C, et al. 2015. Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth. Cell 162:1242-56
117. Mineharu Y, Kamran N, Lowenstein PR, Castro MG. 2014. Blockade of mTOR signaling via rapamycin combined with immunotherapy augments antiglioma cytotoxic and memory T-cell functions. Mol. Cancer Ther. 13:3024-36
118. Gammon JM, Gosselin EA, Tostanoski LH, Chiu YC, Zeng X, et al. 2017. Low-dose controlled release of mTOR inhibitors maintains T cell plasticity and promotes central memory T cells. J. Control Release 263:151-61
119. Guggino G, Scotta C, Lombardi G, Dieli F, Sireci G. 2017. Invariant natural killer T cells treated with rapamycin or transforming growth factor-beta acquire a regulatory function and suppress T effector lymphocytes. Cell Mol. Immunol. 14:392-94
120. Scharping NE, Menk AV, Whetstone RD, Zeng X, Delgoffe GM. 2017. Efficacy of PD-1 blockade is potentiated by metformin-induced reduction of tumor hypoxia. Cancer Immunol. Res. 5:9-16
121. Alfei F, Zehn D. 2017. T cell exhaustion: an epigenetically imprinted phenotypic and functional makeover. Trends Mol. Med. 23:769-71
122. + T cells. Immunity 42:265-78
123. + T cells responding to viral infection. Immunity 45:1327-40
124. Amit I, Winter DR, Jung S. 2016. The role of the local environment and epigenetics in shaping macrophage identity and their effect on tissue homeostasis. Nat. Immunol. 17:18-25
125. Monticelli S, Natoli G. 2017. Transcriptional determination and functional specificity of myeloid cells: making sense of diversity. Nat. Rev. Immunol. 17:595-607
126. + T cells. Immunol. Rev. 211:81-92
127. + cytotoxic T-cell responses during chronic viral infection. J. Virol. 68:8056-63
128. Mueller SN, Ahmed R. 2009. High antigen levels are the cause of T cell exhaustion during chronic viral infection. PNAS 106:8623-28
129. Utzschneider DT, Alfei F, Roelli P, Barras D, Chennupati V, et al. 2016. High antigen levels induce an exhausted phenotype in a chronic infection without impairing T cell expansion and survival. J. Exp. Med. 213:1819-34
130. + T cell exhaustion. J. Immunol. 182:6697-708
131. + T cells. PLOS Med. 5:e100
132. Reignat S, Webster GJ, Brown D, Ogg GS, King A, et al. 2002. Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection. J. Exp. Med. 195:1089-101
133. El-Far M, Halwani R, Said E, Trautmann L, Doroudchi M, et al. 2008. T-cell exhaustion in HIV infection. Curr. HIV/AIDS Rep. 5:13-19
134. Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, et al. 2007. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J. Virol. 81:4215-25
135. Brooks DG, McGavern DB, Oldstone MB. 2006. Reprogramming of antiviral T cells prevents inactivation and restores T cell activity during persistent viral infection. J. Clin. Investig. 116:1675-85
136. Angelosanto JM, Blackburn SD, Crawford A, Wherry EJ. 2012. Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection. J. Virol. 86:8161-70
137. Penaloza-MacMaster P, Provine NM, Blass E, Barouch DH. 2015. CD4 T cell depletion substantially augments the rescue potential of PD-L1 blockade for deeply exhausted CD8 T cells. J. Immunol. 195:1054-63
138. Curtsinger JM, Mescher MF. 2010. Inflammatory cytokines as a third signal for T cell activation. Curr. Opin. Immunol. 22:333-40
139. + T cell fates via the graded expression of T-bet transcription factor. Immunity 27:281-95
140. + T-cell memory. Nat. Rev. Immunol. 8:107-19
141. + T cell memory. Immunity 40:801-13
142. Wilson EB, Brooks DG. 2011. The role of IL-10 in regulating immunity to persistent viral infections. Curr. Top. Microbiol. Immunol. 350:39-65
143. Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, Oldstone MB. 2006. Interleukin-10 determines viral clearance or persistence in vivo. Nat. Med. 12:1301-9
144. Brooks DG, Ha SJ, Elsaesser H, Sharpe AH, Freeman GJ, Oldstone MB.2008. IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection. PNAS 105:20428-33
145. + T cell activation during HIV infection. Nat. Med. 16:452-59
146. Couper KN, Blount DG, Riley EM. 2008. IL-10: the master regulator of immunity to infection. J. Immunol. 180:5771-77
147. Yi JS, Cox MA, Zajac AJ. 2010. T-cell exhaustion: characteristics, causes and conversion. Immunology 129:474-81
148. Knapp S, Hennig BJ, Frodsham AJ, Zhang L, Hellier S, et al. 2003. Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. Immunogenetics 55:362-69
149. Miyazoe S, Hamasaki K, Nakata K, Kajiya Y, Kitajima K, et al. 2002. Influence of interleukin-10 gene promoter polymorphisms on disease progression in patients chronically infected with hepatitis B virus. Am. J. Gastroenterol. 97:2086-92
150. Shin HD, Winkler C, Stephens JC, Bream J, Young H, et al. 2000. Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. PNAS 97:14467-72
151. Ejrnaes M, Filippi CM, Martinic MM, Ling EM, Togher LM, et al. 2006. Resolution of a chronic viral infection after interleukin-10 receptor blockade. J. Exp. Med. 203:2461-72
152. Ni G, Wang T, Walton S, Zhu B, Chen S, et al. 2015. Manipulating IL-10 signalling blockade for better immunotherapy. Cell Immunol. 293:126-29
153. Derynck R, Zhang YE. 2003. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425:577-84
154. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. 2006. Transforming growth factor-beta regulation of immune responses. Annu. Rev. Immunol. 24:99-146
155. Gorelik L, Constant S, Flavell RA. 2002. Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation. J. Exp. Med. 195:1499-505
156. + T cell deletion and viral persistence in vivo. Immunity 31:145-57
157. Kekow J, Wachsman W, McCutchan JA, Gross WL, Zachariah M, et al. 1991. Transforming growth factor-beta and suppression of humoral immune responses in HIV infection. J. Clin. Investig. 87:1010-6
158. Nelson DR, Gonzalez-Peralta RP, Qian K, Xu Y, Marousis CG, et al. 1997. Transforming growth factorbeta 1 in chronic hepatitis C. J. Viral Hepat. 4:29-35
159. + T cell responses in acute and chronic viral infections. Eur. J. Immunol. 37:1502-12
160. Blattman JN, Grayson JM, Wherry EJ, Kaech SM, Smith KA, Ahmed R. 2003. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat. Med. 9:540-47
161. West EE, Jin HT, Rasheed AU, Penaloza-Macmaster P, Ha SJ, et al. 2013. PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. J. Clin. Investig. 123:2604-15
162. Boyman O, Surh CD, Sprent J. 2006. Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease. Expert Opin. Biol. Ther. 6:1323-31
163. INSIGHT-ESPRIT Study Group, SILCAAT Sci. Committee, Abrams D, Levy Y, Losso MH, et al. 2009. Interleukin-2 therapy in patients with HIV infection. N. Engl. J. Med. 361:1548-59
164. + T-cell proliferation in interleukin-2-treated human immunodeficiency virus-positive subjects. Cytometry 46:233-37
165. Marchetti G, Meroni L, Molteni C, Bandera A, Franzetti F, et al. 2004. Interleukin-2 immunotherapy exerts a differential effect on CD4 and CD8 T cell dynamics. AIDS 18:211-16
166. Elsaesser H, Sauer K, Brooks DG. 2009. IL-21 is required to control chronic viral infection. Science 324:1569-72
167. Frohlich A, Kisielow J, Schmitz I, Freigang S, Shamshiev AT, et al. 2009. IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. Science 324:1576-80
168. Yi JS, Du M, Zajac AJ. 2009. A vital role for interleukin-21 in the control of a chronic viral infection. Science 324:1572-76
169. Micci L, Ryan ES, Fromentin R, Bosinger SE, Harper JL, et al. 2015. Interleukin-21 combined with ART reduces inflammation and viral reservoir in SIV-infected macaques. J. Clin. Investig. 125:4497-513
170. Spolski R, Leonard WJ. 2008. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu. Rev. Immunol. 26:57-79
171. Fahey LM, Wilson EB, Elsaesser H, Fistonich CD, McGavern DB, Brooks DG. 2011. Viral persistence redirects CD4 T cell differentiation toward T follicular helper cells. J. Exp. Med. 208:987-99
172. FH cells link immune suppression and adaptive memory in human breast cancer. JCI Insight 2:91487
173. FH cells play defense in cancer and offense in arthritis. Trends Immunol. 38:875-78
174. Xin G, Schauder DM, Lainez B, Weinstein JS, Dai Z, et al. 2015. A critical role of IL-21-induced BATF in sustaining CD8-T-cell-mediated chronic viral control. Cell Rep. 13:1118-24
175. + T cells. Nat. Immunol. 15:373-83
176. + T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nat. Med. 16:1147-51
177. McNab F, Mayer-Barber K, Sher A, Wack A, O'Garra A. 2015. Type I interferons in infectious disease. Nat. Rev. Immunol. 15:87-103
178. Montoya M, Schiavoni G, Mattei F, Gresser I, Belardelli F, et al. 2002. Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood 99:3263-71
179. Papatriantafyllou M. 2013. Regulatory T cells: distilling regulatory T cell inducers. Nat. Rev. Immunol. 13:546
180. Marshall HD, Urban SL, Welsh RM. 2011. Virus-induced transient immune suppression and the inhibition of T cell proliferation by type I interferon. J. Virol. 85:5929-39
181. Kaser A, Nagata S, Tilg H. 1999. Interferon alpha augments activation-induced T cell death by upregulation of Fas (CD95/APO-1) and Fas ligand expression. Cytokine 11:736-43
182. Wu T, Ji Y, Moseman EA, Xu HC, Manglani M, et al. 2016. The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness. Sci. Immunol. 1:eaai8593
183. Teijaro JR, Ng C, Lee AM, Sullivan BM, Sheehan KC, et al. 2013. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 340:207-11
184. Wilson EB, Yamada DH, Elsaesser H, Herskovitz J, Deng J, et al. 2013. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 340:202-7
185. Sandler NG, Bosinger SE, Estes JD, Zhu RT, Tharp GK, et al. 2014. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature 511:601-5
186. Cheng L, Ma J, Li J, Li D, Li G, et al. 2017. Blocking type I interferon signaling enhances T cell recovery and reduces HIV-1 reservoirs. J. Clin. Investig. 127:269-79
187. Zhen A, Rezek V, Youn C, Lam B, Chang N, et al. 2017. Targeting type I interferon-mediated activation restores immune function in chronic HIV infection. J. Clin. Investig. 127:260-68
188. Kalinski P. 2012. Regulation of immune responses by prostaglandin E2. J. Immunol. 188:21-28
189. Harris SG, Padilla J, Koumas L, Ray D, Phipps RP. 2002. Prostaglandins as modulators of immunity. Trends Immunol. 23:144-50
190. Linnemeyer PA, Pollack SB. 1993. Prostaglandin E2-induced changes in the phenotype, morphology, and lytic activity of IL-2-activated natural killer cells. J. Immunol. 150:3747-54
191. Chen JH, Perry CJ, Tsui YC, Staron MM, Parish IA, et al. 2015. Prostaglandin E2 and programmed cell death 1 signaling coordinately impair CTL function and survival during chronic viral infection. Nat. Med. 21:327-34
192. + Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 110:1225-32
193. Kobie JJ, Shah PR, Yang L, Rebhahn JA, Fowell DJ, Mosmann TR. 2006. T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5′-adenosine monophosphate to adenosine. J. Immunol. 177:6780-86
194. Horenstein AL, Chillemi A, Zaccarello G, Bruzzone S, Quarona V, et al. 2013. A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes. Oncoimmunology 2:e26246
195. + T cells. PLOS Pathog. 11:e1005177
196. + T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature 557:575-79
197. Saucillo DC, Gerriets VA, Sheng J, Rathmell JC, MacIver NJ. 2014. Leptin metabolically licenses T cells for activation to link nutrition and immunity. J. Immunol. 192:136-44
198. Michalek RD, Rathmell JC. 2010. The metabolic life and times of a T-cell. Immunol. Rev. 236:190-202
199. Molon B, Ugel S, Del Pozzo F, Soldani C, Zilio S, et al. 2011. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J. Exp. Med. 208:1949-62
200. Frey AB. 2015. Suppression of T cell responses in the tumor microenvironment. Vaccine 33:7393-400
201. Teague TK, Marrack P, Kappler JW, Vella AT. 1997. IL-6 rescues resting mouse T cells from apoptosis. J. Immunol. 158:5791-96
202. + T lymphocytes. J. Immunol. 180:7958-68
203. Baxter AE, Kaufmann DE. 2016. Tumor-necrosis factor is a master of T cell exhaustion. Nat. Immunol. 17:476-78
204. Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, et al. 2012. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 72:917-27
205. Turnis ME, Sawant DV, Szymczak-Workman AL, Andrews LP, Delgoffe GM, et al. 2016. Interleukin-35 limits anti-tumor immunity. Immunity 44:316-29
206. Zhang S, Zhang H, Zhao J. 2009. The role of CD4 T cell help for CD8 CTL activation. Biochem. Biophys. Res. Commun. 384:405-8
207. Veiga-Parga T, Sehrawat S, Rouse BT. 2013. Role of regulatory T cells during virus infection. Immunol. Rev. 255:182-96
208. Ng CT, Snell LM, Brooks DG, Oldstone MB. 2013. Networking at the level of host immunity: immune cell interactions during persistent viral infections. Cell Host Microbe 13:652-64
209. Goh C, Narayanan S, Hahn YS. 2013. Myeloid-derived suppressor cells: the dark knight or the joker in viral infections? Immunol. Rev. 255:210-21
210. Waggoner SN, Cornberg M, Selin LK, Welsh RM. 2011. Natural killer cells act as rheostats modulating antiviral T cells. Nature 481:394-98
211. + Treg activity enhances the immune response to viral infection. PNAS 110:21089-94
212. + regulatory T cell subset that mediates suppression through the chemokine CC chemokine ligand 4. PNAS 104:8029-34
213. Virgin HW, Wherry EJ, Ahmed R. 2009. Redefining chronic viral infection. Cell 138:30-50
214. Odorizzi PM, Wherry EJ. 2012. Inhibitory receptors on lymphocytes: insights from infections. J. Immunol. 188:2957-65
215. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. 2002. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. PNAS 99:12293-97
216. Liang SC, Latchman YE, Buhlmann JE, Tomczak MF, Horwitz BH, et al. 2003. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur. J. Immunol. 33:2706-16
217. Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. 2004. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J. Immunol. 173:945-54
218. Sheppard KA, Fitz LJ, Lee JM, Benander C, George JA, et al. 2004. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3ζ signalosome and downstream signaling to PKCθ. FEBS Lett. 574:37-41
219. Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, Hashimoto-Tane A, Azuma M, Saito T. 2012. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J. Exp. Med. 209:1201-17
220. Rota G, Niogret C, Dang AT, Barros CR, Fonta NP, et al. 2018. Shp-2 is dispensable for establishing T cell exhaustion and for PD-1 signaling in vivo. Cell Rep. 23:39-49
221. + T cells. J. Exp. Med. 212:1125-37
222. Frebel H, Nindl V, Schuepbach RA, Braunschweiler T, Richter K, et al. 2012. Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice. J. Exp. Med. 209:2485-99
223. Topalian SL, Drake CG, Pardoll DM. 2015. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27:450-61
224. Kazandjian D, Khozin S, Blumenthal G, Zhang L, Tang S, et al. 2016. Benefit-risk summary of nivolumab for patients withmetastatic squamous cell lung cancer after platinum-based chemotherapy: a report from the US Food and Drug Administration. JAMA Oncol. 2:118-22
225. Curran MA, Montalvo W, Yagita H, Allison JP. 2010. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. PNAS 107:4275-80
226. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, et al. 2017. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357:409-13
227. Lee CH, Yelensky R, Jooss K, Chan TA. 2018. Update on tumor neoantigens and their utility: why it is good to be different. Trends Immunol. 39:536-48
228. Turnis ME, Andrews LP, Vignali DA. 2015. Inhibitory receptors as targets for cancer immunotherapy. Eur. J. Immunol. 45:1892-905
229. + T cell effector function. Cancer Cell 26:923-37
230. Yu X, Harden K, Gonzalez LC, Francesco M, Chiang E, et al. 2009. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat. Immunol. 10:48-57
231. + T cells in melanoma patients. J. Clin. Investig. 125:2046-58
232. Workman CJ, Dugger KJ, Vignali DA. 2002. Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3. J. Immunol. 169:5392-95
233. Richter K, Agnellini P, Oxenius A. 2010. On the role of the inhibitory receptor LAG-3 in acute and chronic LCMV infection. Int. Immunol. 22:13-23
234. Kuchroo VK, Dardalhon V, Xiao S, Anderson AC. 2008. New roles for TIM family members in immune regulation. Nat. Rev. Immunol. 8:577-80
235. Jin HT, Anderson AC, Tan WG, West EE, Ha SJ, et al. 2010. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. PNAS 107:14733-38
236. + T cells that provide the proliferative burst after PD-1 therapy. Nature 537:417-20
237. Vali B, Yue FY, Jones RB, Sheth PM, Kaul R, et al. 2008. HIV-specific T-cells accumulate in the liver in HCV/HIV co-infection. PLOS ONE 3:e3454
238. + T cells. J. Virol. 83:9122-30
239. Jones RB, Ndhlovu LC, Barbour JD, Sheth PM, Jha AR, et al. 2008. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J. Exp. Med. 205:2763-79
240. + HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J. Clin. Investig. 120:4546-57
241. Nebbia G, Peppa D, Schurich A, Khanna P, Singh HD, et al. 2012. Upregulation of the Tim-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection. PLOS ONE 7:e47648
242. + T-cell response in patients with chronic hepatitis B. Eur. J. Immunol. 42:1180-91
243. Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JA. 2016. CD28 costimulation: from mechanism to therapy. Immunity 44:973-88
244. Croft M. 2009. The role of TNF superfamily members in T-cell function and diseases. Nat. Rev. Immunol. 9:271-85
245. Boettler T, Moeckel F, Cheng Y, Heeg M, Salek-Ardakani S, et al. 2012. OX40 facilitates control of a persistent virus infection. PLOS Pathog. 8:e1002913
246. Penaloza-MacMaster P, Ur Rasheed A, Iyer SS, Yagita H, Blazar BR, Ahmed R. 2011. Opposing effects of CD70 costimulation during acute and chronic lymphocytic choriomeningitis virus infection of mice. J. Virol. 85:6168-74
247. Vezys V, Penaloza-MacMaster P, Barber DL, Ha SJ, Konieczny B, et al. 2011. 4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection. J. Immunol. 187:1634-42
248. Guedan S, Posey AD Jr., Shaw C, Wing A, Da T, et al. 2018. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. JCI Insight 3:96976
249. Dolfi DV, Mansfield KD, Polley AM, Doyle SA, Freeman GJ, et al. 2013. Increased T-bet is associated with senescence of influenza virus-specific CD8 T cells in aged humans. J. Leukoc. Biol. 93:825-36
250. Xu W, Larbi A. 2017. Markers of T cell senescence in humans. Int. J. Mol. Sci. 18:E1742
251. FH cells during acute viral infection. Nat. Immunol. 16:991-99
252. + T cell fate coupled by T-bet and eomesodermin. Nat. Immunol. 6:1236-44
253. + T cell function by the transcription factor Eomesodermin. Science 302:1041-43
254. Sullivan BM, Juedes A, Szabo SJ, von Herrath M, Glimcher LH. 2003. Antigen-driven effector CD8 T cell function regulated by T-bet. PNAS 100:15818-23
255. + T cells to compete for the memory cell niche. J. Immunol. 185:4988-92
256. + T cells. J. Exp. Med. 204:2015-21
257. Pipkin ME, Sacks JA, Cruz-Guilloty F, Lichtenheld MG, Bevan MJ, Rao A. 2010. Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. Immunity 32:79-90
258. + T cells depend on T cell factor 1. Immunity 33:229-40
259. Dominguez CX, Amezquita RA, Guan T, Marshall HD, Joshi NS, et al. 2015. The transcription factors ZEB2 and T-bet cooperate to program cytotoxic T cell terminal differentiation in response to LCMV viral infection. J. Exp. Med. 212:2041-56
260. + T cell exhaustion and limits the development of memory-like T cells during chronic infection. Immunity 47:1129-41.e5
261. Crabtree GR, Olson EN. 2002. NFAT signaling: choreographing the social lives of cells. Cell 109(Suppl.):S67-79
262. Rao A, Luo C, Hogan PG. 1997. Transcription factors of the NFAT family: regulation and function. Annu. Rev. Immunol. 15:707-47
263. Macian F, Garcia-Cozar F, Im SH, Horton HF, Byrne MC, Rao A. 2002. Transcriptional mechanisms underlying lymphocyte tolerance. Cell 109:719-31
264. + channels in dispersed bovine parathyroid cells. J. Surg. Res. 76:37-40
265. Macian F, Garcia-Rodriguez C, Rao A. 2000. Gene expression elicited by NFAT in the presence or absence of cooperative recruitment of Fos and Jun. EMBO J. 19:4783-95
266. Oestreich KJ, Yoon H, Ahmed R, Boss JM. 2008. NFATc1 regulates PD-1 expression upon T cell activation. J. Immunol. 181:4832-39
267. Stelekati E, Chen A, Manne S, Kurachi M, Ali MA, et al. 2018. Long-term persistence of exhausted CD8 T cells in chronic infection is regulated by microRNA-155. Cell Rep. 7:2142-56
268. Hess Michelini R, Doedens AL, Goldrath AW, Hedrick SM. 2013. Differentiation of CD8 memory T cells depends on Foxo1. J. Exp. Med. 210:1189-200
269. Martins GA, Hutchins AS, Reiner SL. 2005. Transcriptional activators of helper T cell fate are required for establishment but not maintenance of signature cytokine expression. J. Immunol. 175:5981-85
270. Murphy TL, Tussiwand R, Murphy KM. 2013. Specificity through cooperation: BATF-IRF interactions control immune-regulatory networks. Nat. Rev. Immunol. 13:499-509
271. Shi W, Man K, Smyth GK, Nutt SL, Kallies A. 2014. Whole transcriptome analysis for T cell receptoraffinity and IRF4-regulated clonal expansion of T cells. Genom. Data 2:396-98
272. Man K, Miasari M, Shi W, Xin A, Henstridge DC, et al. 2013. The transcription factor IRF4 is essential for TCR affinity-mediated metabolic programming and clonal expansion of T cells. Nat. Immunol. 14:1155-65
273. + T cell expansion and effector differentiation. Immunity 39:833-45
274. + T-cell function following infection with LCMV. Cell Death Differ. 21:1050-60
275. + T cell effector programming confers early memory properties and phenotypic diversity. PNAS 114:E8865-74
276. Haase VH. 2006. The VHL/HIF oxygen-sensing pathway and its relevance to kidney disease. Kidney Int. 69:1302-7
277. + T cells in chronic viral infection. J. Immunol. 195:2103-14
278. Buenrostro JD, Wu B, Chang HY, Greenleaf WJ. 2015. ATAC-seq: a method for assaying chromatin accessibility genome-wide. Curr. Protoc. Mol. Biol. 109:21.29.1-9
279. + tumor-infiltrating T cells. PNAS 114:E2776-85
280. Lu P, Youngblood BA, Austin JW, Mohammed AU, Butler R, et al. 2014. Blimp-1 represses CD8 T cell expression of PD-1 using a feed-forward transcriptional circuit during acute viral infection. J. Exp. Med. 211:515-27
281. Ghoneim HE, Fan Y, Moustaki A, Abdelsamed HA, Dash P, et al. 2017. De novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenation. Cell 170:142-57.e19
282. Austin JW, Lu P, Majumder P, Ahmed R, Boss JM. 2014. STAT3, STAT4, NFATc1, and CTCF regulate PD-1 through multiple novel regulatory regions in murine T cells. J. Immunol. 192:4876-86
283. + T cells tolerized by peptide immunotherapy. eLife 3:e03416
284. + T cells. Immunity 35:400-12
285. + T cells from chronic viral infection. Mol. Ther. 22:1698-706
286. Leach DR, Krummel MF, Allison JP. 1996. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734-36
287. Lonberg N, Korman AJ. 2017. Masterful antibodies: checkpoint blockade. Cancer Immunol. Res. 5:275-81
288. + T cell levels in humanized mice. J. Immunol. 190:211-19
289. Seung E, Dudek TE, Allen TM, Freeman GJ, Luster AD, Tager AM. 2013. PD-1 blockade in chronically HIV-1-infected humanized mice suppresses viral loads. PLOS ONE 8:e77780
290. Zippelius A, Batard P, Rubio-Godoy V, Bioley G, Lienard D, et al. 2004. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res. 64:2865-73
291. Sznol M, Chen L. 2013. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin. Cancer Res. 19:1021-34
292. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, et al. 2002. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8:793-800
293. Ribas A, Wolchok JD. 2018. Cancer immunotherapy using checkpoint blockade. Science 359:1350-55
294. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, et al. 2013. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369:122-33
295. Balachandran VP, Luksza M, Zhao JN, Makarov V, Moral JA, et al. 2017. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature 551:512-16
296. Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, et al. 2015. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520:373-77
297. + CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. PNAS 114:4993-98
298. Grosso JF, Goldberg MV, Getnet D, Bruno TC, Yen HR, et al. 2009. Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J. Immunol. 182:6659-69
299. Butler NS, Moebius J, Pewe LL, Traore B, Doumbo OK, et al. 2011. Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection. Nat. Immunol. 13:188-95
300. Turnis ME, Korman AJ, Drake CG, Vignali DA. 2012. Combinatorial Immunotherapy: PD-1 may not be LAG-ing behind any more. Oncoimmunology 1:1172-74
301. Chong EA, Melenhorst JJ, Lacey SF, Ambrose DE, Gonzalez V, et al. 2017. PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. Blood 129:1039-41
302. Ren J, Liu X, Fang C, Jiang S, June CH, Zhao Y. 2017. Multiplex genome editing to generate universal CAR T cells resistant to PD-1 inhibition. Clin. Cancer Res. 23:2255-66
303. Kurachi M, Kurachi J, Chen Z, Johnson J, Khan O, et al. 2017. Optimized retroviral transduction of mouse T cells for in vivo assessment of gene function. Nat. Protoc. 12:1980-98
304. Pegram HJ, Andrews DM, Smyth MJ, Darcy PK, Kershaw MH. 2011. Activating and inhibitory receptors of natural killer cells. Immunol. Cell Biol. 89:216-24
305. Sharma P, Allison JP. 2015. The future of immune checkpoint therapy. Science 348:56-61
306. Guo Z, Wang X, Cheng D, Xia Z, Luan M, Zhang S. 2014. PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer. PLOS ONE 9:e89350
307. Jure-Kunkel M, Masters G, Girit E, Dito G, Lee F, et al. 2013. Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models. Cancer Immunol. Immunother. 62:1533-45
308. Budhu S, Schaer DA, Li Y, Toledo-Crow R, Panageas K, et al. 2017. Blockade of surface-bound TGF-β on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment. Sci. Signal. 10:eaak9702
309. Mittal D, Young A, Stannard K, Yong M, Teng MW, et al. 2014. Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. Cancer Res. 74:3652-58
310. Gay F, D'Agostino M, Giaccone L, Genuardi M, Festuccia M, et al. 2017. Immuno-oncologic approaches: CAR-T cells and checkpoint inhibitors. Clin. Lymphoma Myeloma Leuk. 17:471-78